Fusion Antibodies, a drug discovery spin-out of Queen’s University Belfast, will be able to further develop its capacity to produce cancer-fighting drugs following support from government agency Invest NI (Northern Ireland).
The agency, which is distributing cash from the European Regional Development Fund, will put £63,304 ($103k) into the firm, of which £22,704 is earmarked for research and development. The rest of the funding will be used to assist the spin-out in setting up the international marketing of its research services.
Tracy Meharg, Invest NI’s executive director of business solutions, said: “Fusion Antibodies is at the forefront of the development and sequencing of antibodies for use in the diagnosis and therapeutic treatment of cancer and other diseases. The company offers expertise that can help to accelerate the development of human drugs from programmes carried out by researchers in international pharmaceutical organisations and university labs.”
